[ad_1]
LOUISVILLE, Texas–(BUSINESS WIRE)– Orthofix Medical Co., Ltd. (NASDAQ:OFIX), a leading global spine and orthopedic company, today announced the appointment of Jason Shallenberger as President of its Bone Growth Therapies business, reorganizing its Spine business unit, effective March 1. Did. Mr. Shallenberger was previously an experienced sales leader. He served as vice president of U.S. sales and marketing for the Orthofix Bone Growth Therapies business.
This press release features multimedia. Read the full release here: https://www.businesswire.com/news/home/20240229167353/en/
Orthofix names Jason Shallenberger as President of Bone Growth Therapies (Photo: Business Wire)
Prior to this reorganization, our Bone Growth Therapy business was managed under the direction of our Spine business unit. Bone Growth Therapy and Spine will be led by separate presidents, consistent with the current business structure of Biologics and Enabling Technologies.
“Jason has led the sales and marketing of this successful franchise for many years,” said Massimo Calafiore, President and CEO of Orthofix. “Under his leadership, our sales team achieved double-digit quarterly growth in 2023. I am confident that he will do a great job as president and continue to make a significant contribution to Orthofix’s success. I am.”
“Since 1986, Orthofix Bone Growth Therapy has helped accelerate the natural bone healing process in patients,” said Shallenberger. “I am honored to continue my career in this new role as our company continues to innovate and bring new technologies to market.”
Mr. Shallenberger joined Orthofix in 2005 as a Territory Manager, quickly moved into the role of District Sales Manager, and was promoted to the position of Regional Sales Director in 2008. He was promoted to Vice President of U.S. Sales and Marketing in 2011 and led a team that has achieved 30 consecutive quarters of year-over-year growth, outpacing the market’s annual growth rate, and added medical education in 2023. I was given responsibility. Prior to joining Orthofix, Mr. Shalenberger worked as a professional sales representative at Boehringer Ingelheim Pharmaceuticals. He is a graduate of the University of Nebraska.
About bone growth therapy
The Orthofix bone growth therapy device provides a safe, non-invasive treatment to aid in non-healing or difficult-to-heal fractures and spinal fusion procedures. This device stimulates the bone’s natural healing process by sending low-level pulses of electromagnetic energy or pulsed ultrasound to the site of injury or nonunion. A market leader in the field of bone growth stimulation, Orthofix’s Pulsed Electromagnetic Field Stimulation (PEMF) devices have treated more than 1 million patients to date. In 2022 Orthofix launches his AccelStim™ Devices with low-intensity pulsed ultrasound (LIPUS) technology. A non-surgical treatment for new or non-healing fractures (non-unions). This system is part of the PEMF device portfolio consisting of SpinalStim.™,CervicalStim™ and physiostim™ system. For more information about Bone Growth Therapy, visit bonegrowththerapy.com.
Orthofix is a leading global spine and orthopedic company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and state-of-the-art surgical navigation systems. is. Its products are sold in more than 60 countries around the world.
The company is headquartered in Lewisville, Texas, with general operations, product development, medical education and manufacturing operations, and has a principal office in Carlsbad, California, with a focus on spine and biologics product innovation and surgeon education. I am putting It is also based in Verona, Italy. It focuses on product innovation, production, and medical education for orthopedics. The combined company’s global R&D, commercial and manufacturing locations include Irvine, California; Toronto, Canada; Sunnyvale, California; Wayne, Pennsylvania; Olive Branch, Mississippi; Maidenhead, UK; Munich, Germany; Also includes facilities and offices in Paris and São Paulo. Paulo, Brazil.
Forward-looking statements
This news release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “plan”, as the case may be. You can identify forward-looking statements by terms such as , “anticipate,” “anticipate,” and similar terms. “intends,” “anticipates,” “may,” “continues,” or other comparable terms. Orthofix cautions you that statements contained in this news release that are not statements of historical fact are forward-looking statements that are based on the company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and meet the needs of surgeons and patients, including due to the lack of robust clinical validation; and under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the Securities and Exchange Commission (SEC) on March 6. Identified Risks The Company’s filings with the Securities and Exchange Commission are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Orthofix does not intend to revise or update the forward-looking statements contained in this news release to reflect events or circumstances occurring after the date hereof, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240229167353/en/
[ad_2]
Source link
